Share-based Payment Arrangement, Expense in USD of Revolution Medicines, Inc. from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Revolution Medicines, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to Q3 2025.
  • Revolution Medicines, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $30.8M, a 48.2% increase year-over-year.
  • Revolution Medicines, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $107M, a 30.4% increase year-over-year.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $79.2M, a 28.2% increase from 2023.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $61.8M, a 98% increase from 2022.
  • Revolution Medicines, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $31.2M, a 50.5% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Revolution Medicines, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $107M $30.8M +$10M +48.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $97.1M $28.8M +$9.06M +45.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-06
Q1 2025 $88.1M $25.1M +$8.88M +54.8% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $79.2M $22.4M -$2.99M -11.8% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-26
Q3 2024 $82.2M $20.8M +$7.11M +52% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $75.1M $19.8M +$6.8M +52.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-06
Q1 2024 $68.3M $16.2M +$6.51M +67.1% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $61.8M $25.4M +$17.1M +206% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-26
Q3 2023 $44.7M $13.7M +$5.53M +67.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $39.1M $13M +$4.88M +60.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $34.3M $9.7M +$3.06M +46% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $31.2M $8.32M +$2.12M +34.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-26
Q3 2022 $29.1M $8.14M +$2.31M +39.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $26.8M $8.1M +$2.79M +52.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $24M $6.64M +$3.26M +96.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $20.7M $6.2M +$3.57M +135% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $17.2M $5.83M +$3.16M +118% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $14M $5.31M +$3.3M +163% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $10.7M $3.39M +$1.82M +116% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $8.89M $2.63M +$1.23M +88.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $7.65M $2.67M +$1.82M +213% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $5.84M $2.02M +$1.51M +299% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $4.33M $1.57M +$1.16M +289% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $3.16M $1.4M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 $854K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $505K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $403K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14

Revolution Medicines, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $79.2M +$17.4M +28.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-26
2023 $61.8M +$30.6M +98% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-26
2022 $31.2M +$10.5M +50.5% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-26
2021 $20.7M +$11.8M +133% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-26
2020 $8.89M +$5.73M +181% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $3.16M +$2.31M +270% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $855K Jan 1, 2018 Dec 31, 2018 10-K 2021-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.